Log In      Register Advertisement
Managed Care

Age, coverage erase racial, ethnic differences in men's use of depression, anxiety treatment

MANAGED CARE July 2015. © MediMedia USA
News & Commentary

Age, coverage erase racial, ethnic differences in men's use of depression, anxiety treatment

Black and Hispanic men suffering from depression or anxiety are less likely to get help than white men, but the racial and ethnic differences narrow and even reverse with age and insurance coverage, according to a CDC report on men’s use of mental health treatment.

When researchers at the CDC’s National Center for Health Statistics analyzed survey data on more than 21,000 American men, they found that nearly 1 in 10 adult American men had daily bouts of depression or anxiety, but less than half (41%) of those men received treatment for their problems by either taking medication (33%) or talking with a mental health professional (25.7%).

Racial and ethnic disparity changes with age, insurance

Percentage of men reporting symptoms of depression or anxiety who received treatment

Source: CDC/NCHS, National Health Interview Survey, 2010–2013

The CDC researchers found that 26.4% of young (ages 18 to 44) black and Hispanic men with anxiety and depression sought treatment, compared with 45.4% of white men. But with age, the picture changes; in fact, among older men (ages 45 and older), a slightly greater percentage (46.4%) of black and Hispanic men seek treatment compared with white men (41.3%).

When they looked at associations with insurance coverage, the CDC statisticians found large racial and ethnic differences among the young and uninsured: White men (39.3%) were three times more likely to seek treatment as black and Hispanic men (12.7%). But among the young with insurance, the difference narrowed (48.4% vs. 38.7%) and was not statistically significant.

The researchers noted that in focus groups, young men of color were much more likely to say that seeking treatment for mental illness is a sign of weakness but, again, “Having health insurance appeared to reduce the impact of such barriers… Recent expansions of health insurance coverage may consequently reduce these racial and ethnic disparities.”


Explore the complexities of the biosimilars’ landscape, such as naming, interchangeability and substitution, differences in the manufacturing processes, as well as the approval pathways & FDA guidelines for biologics, including draft guidance on biosimilars.


News & Commentary
Finally, a success story for the struggling health insurance exchange (HIE) effort. Researchers were able to accurately predict health care utilization in Maine for more than a million patients for six months using only demographic and electronic medical records (EMRs) data from the previous year.
News & Commentary
Emergency surgeries for ulcerative colitis and Crohn’s disease are often performed by less experienced physicians and can occur during off-hours and weekends, when there’s fewer people working, says a meta-analysis in Gastroenterology. The lower risk of elective surgery may in part be explained by the greater use of laparoscopic surgery.
Medication Management
Thomas Reinke
Cardinal Health and McKesson see a future in an idea that has had difficulty taking root. They’re betting that MTM and adherence services will become more important as CMS expands its requirements for comprehensive medication reviews in 2016 and as accountable care programs use adherence as a tool to control costs.
News & Commentary
The American College of Physicians likes retail clinics just fine, so long as they are used as backups to the work of primary care physicians, according an ACP position paper in the Annals of Internal Medicine. They are not really equipped to handle chronic conditions, either. The organization representing retail clinics says that most of its members follow these guidelines.
Biologics In Development
Katherine T. Adams
Several commentators at the 2015 European Cancer Congress noted that as good as this and other new immunotherapy drugs may be, they are very costly—and in Europe, several countries with socialized medicine programs will not be able to afford them.
Managed Care Outlook
Reaching benchmarks for risk factor reduction could reduce premature deaths worldwide to 5.7 million in 2025. Those risk factor targets are a 30% decrease in tobacco smoking, a 25% reduction in prevalence of hypertension, no increase in the number of people with diabetes, and no increase in the number of people who are obese.
Tomorrow’s Medicine
Thomas Morrow, MD
A stent called Synergy is the first stent approved in this country as a treatment of coronary artery disease that’s made with a bioresorbable polymer coating. The polymer effectively disappears, leaving behind only the biologically inert bare-metal stent that the body covers with a fresh layer of endothelial tissue.
Original Research
Abhishek Chitnis, MPharm, PhD
Shawn X. Sun, PhD
Shailja Dixit, MD, MPH
Rosa Wang, MHA
The medication did this mostly by reducing the level of inpatient care for over 350 patients in the six months immediately following initiation. Researchers suggest that further studies should confirm this conclusion and also investigate just how long these reductions can be sustained.